Validity, reliability and responsiveness of Euroqol (EQ5D) in patients (Pts) receiving palliative care (PC)

Xia, Qianghua; Hwang, Sun‐Goo; Chang, Victor; Osenenko, P.; Alejandro, Y.; Yan, H.; Toomey, K.; Srinivas, S.

doi:10.1200/jco.2005.23.16_suppl.8082

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 The mean index score at follow-up was essentially unchanged ( P -value=0.3409, paired comparisons from baseline to eight weeks).…”

Section: Resultsmentioning

confidence: 95%

“…The index scale has demonstrated reliability and validity in patients with advanced cancer. 17 It is routinely included in economic analyses because it permits estimation of utilities based on societal valuations of particular health states, which are used to generate quality-adjusted life years, the denominator in calculations of incremental cost-effectiveness ratios. 18 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Romanus

Kindler

Archer³

et al. 2012

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Context Gemcitabine for advanced pancreas cancer (APC) is palliative and prognosis is poor, making health-related quality of life (HRQOL) particularly important. Objectives We evaluated HRQOL with the EuroQol EQ-5D™, in patients with APC participating in Cancer and Leukemia Group B (CALGB) 80303, a multicenter, double-blind, randomized trial comparing overall survival (OS) between two treatment arms, gemcitabine with bevacizumab, or gemcitabine with placebo. Methods A consecutive subsample of patients was invited to complete the EQ-5D surveys. Because neither clinical nor HRQOL outcomes differed based on study arm, analyses were pooled. Changes in mean scores from baseline to eight weeks and the prognostic value of the EQ-5D were evaluated. Results Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P-value=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores. A small decline in visual analogue scale (VAS) scores was observed (70.7 vs. 68.2, P-value=0.026). HRQOL changes within chemotherapy response strata revealed stable index scores, but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease. VAS scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P-value=0.029). Baseline scores from both EQ-5D scales were significant predictors of OS in Cox proportional hazard models. Conclusion Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL. Small improvements in pain and mood are observed despite progressive functional decline. Those who respond to gemcitabine may experience a slight slowing of functional deterioration.

show abstract

“…17 The mean index score at follow-up was essentially unchanged ( P -value=0.3409, paired comparisons from baseline to eight weeks).…”

Section: Resultsmentioning

confidence: 95%

Section: Methodsmentioning

confidence: 99%

Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Romanus

Kindler

Archer³

et al. 2012

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

show abstract

“…The survey methodology was based on the QUALYCARE survey undertaken in London in 2009–2010 (Gomes et al, 2010; 2015). The following tools, with adaptations, were also included: the Client Service Receipt Inventory (McCrone, 2009), the Palliative Outcome Scale (Hearn & Higginson, 1999), and the EuroQoL EQ5D (Xia et al, 2005).…”

Section: Methodsmentioning

confidence: 99%

Insights into the factors associated with achieving the preference of home death in terminal cancer: A national population-based study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We measured the deceased’s health status at 3 months before death (EuroQoL EQ-5D) 26 and the respondent’s intensity of grief at present and at the time of the person’s death (retrospectively) (Texas Revised Inventory of Grief (TRIG)). 27 Information on the cause and place of death was provided by the ONS.…”

Section: Methodsmentioning

confidence: 99%

Home care by general practitioners for cancer patients in the last 3 months of life: An epidemiological study of quality and associated factors

et al. 2015

View full text Add to dashboard Cite

Background:Stronger generalist end-of-life care at home for people with cancer is called for but the quality of end-of-life care delivered by general practitioners has been questioned.Aim:To determine the degree of and factors associated with bereaved relatives’ satisfaction with home end-of-life care delivered by general practitioners to cancer patients.Design:Population-based mortality followback survey.Setting/participants:Bereaved relatives of people who died of cancer in London, United Kingdom (identified from death registrations in 2009–2010), were invited to complete a postal questionnaire surveying the deceased’s final 3 months of life.Results:Questionnaires were completed for 596 decedents of whom 548 spent at least 1 day at home in the last 3 months of life. Of the respondents, 55% (95% confidence interval: 51%–59%) reported excellent/very good home care by general practitioners, compared with 78% (95% confidence interval: 74%–82%) for specialist palliative care providers and 68% (95% confidence interval: 64%–73%) for district/community/private nurses. The odds of high satisfaction (excellent/very good) with end-of-life care by general practitioners doubled if general practitioners made three or more compared with one or no home visits in the patient’s last 3 months of life (adjusted odds ratio: 2.54 (95% confidence interval: 1.52–4.24)) and halved if the patient died at hospital rather than at home (adjusted odds ratio: 0.55 (95% confidence interval: 0.31–0.998)).Conclusion:There is considerable room for improvement in the satisfaction with home care provided by general practitioners to terminally ill cancer patients. Ensuring an adequate offer of home visits by general practitioners may help to achieve this goal.

show abstract

Validity, reliability and responsiveness of Euroqol (EQ5D) in patients (Pts) receiving palliative care (PC)

Cited by 8 publications

References 0 publications

Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Insights into the factors associated with achieving the preference of home death in terminal cancer: A national population-based study

Home care by general practitioners for cancer patients in the last 3 months of life: An epidemiological study of quality and associated factors

Contact Info

Product

Resources

About